COMMUNIQUÉS West-GlobeNewswire

TYME Continues to Expand Pipeline of Cancer Metabolism-Based Therapies to Potentially Benefit Patients with Difficult-to-Treat Cancers

07/03/2019 - 14:00

Targeting IND-enabling program for TYME-18 in 2H2019 NEW YORK, March 07, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME) , an emerging biotechnology company developing cancer metabolism-based therapies ( [...]

Aduro Biotech to Present at Two Upcoming Investor Conferences in March

07/03/2019 - 14:00

BERKELEY, Calif., March 07, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that Aduro management is scheduled to present at the following investor conferences: 39 th Annual Cowen Health Care [...]

Zafgen to Present at the Cowen and Company 39th Annual Health Care Conference

07/03/2019 - 14:00

BOSTON, March 07, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients [...]

Samumed to Present Clinical Data on SM04690 at the American Academy of Orthopaedic Surgeons 2019 Annual Meeting

07/03/2019 - 14:00

SAN DIEGO, March 07, 2019 (GLOBE NEWSWIRE) -- Samumed, LLC, announced today that clinical data from its successful phase 2a trial of SM04690 for the treatment of knee osteoarthritis (OA) has been accepted as a poster [...]

BioSig Technologies to Present at the 31st Annual ROTH Conference

07/03/2019 - 13:52

Santa Monica, CA, March 07, 2019 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical device company developing a proprietary biomedical signal processing platform designed [...]

LIDDS: Collaboration with Belina Pharma concludes

07/03/2019 - 13:46

A collaboration agreement with Belina was signed in 2017 with the aim of using LIDDS depot technology in combination with a drug intended for the treatment of breast cancer. The collaboration has now concluded. LIDDS [...]

Kiniksa Reports Fourth Quarter and Full-Year 2018 Financial Results and Highlights Recent Corporate and Pipeline Activity

07/03/2019 - 13:30

– Enrollment and dosing of patients commenced in rilonacept pivotal Phase 3 trial – Enrollment and dosing of patients commenced in mavrilimumab global Phase 2 trial – KPL-716 advancing into two Phase 2 trials in 1H 2019 [...]

Albireo Reports Year-End 2018 Financial Results and Provides Pipeline Update

07/03/2019 - 13:30

- A4250 Phase 3 PFIC pivotal program on target for end of ‘19/early ’20 topline readout - - Plan to initiate second A4250 pivotal program in biliary atresia - - Plan to initiate Phase 2 study with elobixibat in NASH [...]

Centrexion Therapeutics Announces CNTX-4975 Preclinical and Clinical Data Presentations at the 35th Annual American Academy of Pain Medicine Meeting

07/03/2019 - 13:30

Company will present two posters on CNTX-4975 for treatment of moderate to severe knee osteoarthritis pain; pharmacological data from preclinical and Phase 1 and 2 clinical trials describing the mechanism of action; and [...]

XOMA Reports Fourth Quarter and Full Year 2018 Financial Results and Operating Highlights

07/03/2019 - 13:05

Added seven new partner-funded programs in 2018 with potential for milestone and royalty payments Current cash balance sufficient to fund operations for multiple years EMERYVILLE, Calif., March 07, 2019 (GLOBE NEWSWIRE [...]

Ossur Hf : Board decisions following the Annual General Meeting

07/03/2019 - 13:01

Announcement no. 17/2019 7 March 2019 Board decisions following the Annual General Meeting Enclosed are the Board decisions following the Annual General Meeting of Össur hf. held today, Thursday 7 March 2019. Further [...]

Inivata Publishes Positive Results of Clinical Validation and Utility Study for InVision® Liquid Biopsy Test

07/03/2019 - 13:00

Inivata Publishes Positive Results of Clinical Validation and Utility Study for InVision ® Liquid Biopsy Test Large, real-world, prospective study shows Inivata’s liquid biopsy test is able to provide molecular profile [...]

Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock

07/03/2019 - 13:00

WALTHAM, Mass. and CRESTWOOD, Ky., March 07, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to [...]

Emerald Health Therapeutics’ Licensed Endo Product Wins Taste For Life’s 2019 Essentials Supplement Award in the U.S.

07/03/2019 - 13:00

Novel Emerald endocannabinoid-supporting products well-positioned to develop brand presence and market demand among both cannabis and non-cannabis users SAN DIEGO, March 07, 2019 (GLOBE NEWSWIRE) -- Emerald Health [...]

HEXO Corp to announce second quarter fiscal 2019 results and conference call

07/03/2019 - 12:30

GATINEAU, Quebec, March 07, 2019 (GLOBE NEWSWIRE) -- HEXO Corp (“HEXO” or the “Company”) (TSX: HEXO ; NYSE-A: HEXO ) will release its financial results for the second quarter fiscal 2019 ended January 31 before [...]

HEXO Corp annonce ses résultats du deuxième trimestre de l’exercice 2019

07/03/2019 - 12:30

GATINEAU, Québec, 07 mars 2019 (GLOBE NEWSWIRE) -- HEXO Corp (« HEXO » ou la « Société ») (TSX: HEXO ; NYSE-A : HEXO ) publiera ses résultats financiers du deuxième trimestre de l’exercice 2019, clos le 31 janvier, et [...]

Exactus Announces Retirement of Remaining Convertible Notes

07/03/2019 - 12:30

GLEN ALLEN, Va., March 07, 2019 (GLOBE NEWSWIRE) -- Exactus Inc. (OTCQB: EXDI) , a healthcare company pursuing opportunities in Hemp derived Cannabidiol (CBD) products, today announced that it has retired the last of [...]

Achillion Reports Fourth Quarter and Full Year 2018 Financial Results

07/03/2019 - 12:00

- Phase 2 trial enrollment on schedule in PNH combo, interim data expected in Q2:2019 - - Phase 2 trial enrollment on schedule in C3G, 24 sites recruiting - - Next-generation factor D inhibitor ACH-5228 US IND [...]

Opthea’s Phase 2b Trial in Wet AMD Advances with a Second Positive Independent Safety Committee Recommendation

07/03/2019 - 11:30

MELBOURNE, Australia, March 07, 2019 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT) is pleased to announce that the independent Data and Safety Monitoring Board (DSMB) for the Company’s ongoing Phase 2b study of OPT-302 [...]